Immunocellular OTC Stock Today

IMUC -  USA Stock  

USD 0.62  0.07  12.73%

Immunocellular Therapeutics is trading at 0.62 as of the 20th of October 2021, a 12.73 percent increase since the beginning of the trading day. The stock's open price was 0.55. Immunocellular Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Immunocellular Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of July 2021 and ending today, the 20th of October 2021. Click here to learn more.
 Market Performance
7 of 100
  Odds Of Distress
Over 72
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California. Immunocellular Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. The company has 4.19 M outstanding shares of which 165.95 K shares are currently shorted by private and institutional investors with about 4.13 trading days to cover. More on Immunocellular Therapeutics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Immunocellular Therapeutics OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Immunocellular Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Immunocellular Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Immunocellular Therapeutics is way too risky over 90 days horizon
Immunocellular Therapeutics has some characteristics of a very speculative penny stock
Immunocellular Therapeutics appears to be risky and price may revert if volatility continues
Immunocellular Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 300 K. Net Loss for the year was (9.03 M) with profit before overhead, payroll, taxes, and interest of 0.
Immunocellular Therapeutics currently holds about 2.85 M in cash with (10.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from www.equities.com: Sorrento falls 1.82 percent for October 8 - Equities.com
Legal NameImmunocellular Therapeutics
CEO and President and DirectorAndrew Gengos  (View All)
Average Analyst Recommendation
Analysts covering Immunocellular Therapeutics report their recommendations after researching Immunocellular Therapeutics' financial statements, talking to executives and customers, or listening in on Immunocellular Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Immunocellular Therapeutics. The Immunocellular consensus assessment is calculated by taking the average forecast from all of the analysts covering Immunocellular Therapeutics.
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Immunocellular Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldOvervalued
Immunocellular Therapeutics [IMUC] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Nano-Cap' category with current market capitalization of 2.47 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunocellular Therapeutics's market, we take the total number of its shares issued and multiply it by Immunocellular Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Immunocellular Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 4.19 M outstanding shares of which 165.95 K shares are currently shorted by private and institutional investors with about 4.13 trading days to cover. Immunocellular Therapeutics currently holds about 2.85 M in cash with (10.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Immunocellular Therapeutics Probability Of Bankruptcy

Immunocellular Stock Price Odds Analysis

What are Immunocellular Therapeutics' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Immunocellular Therapeutics jumping above the current price in 90 days from now is about 9.7%. The Immunocellular Therapeutics probability density function shows the probability of Immunocellular Therapeutics otc stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Immunocellular Therapeutics has a beta of -0.4442. This usually indicates as returns on benchmark increase, returns on holding Immunocellular Therapeutics are expected to decrease at a much lower rate. During the bear market, however, Immunocellular Therapeutics is likely to outperform the market. Moreover, the company has an alpha of 1.8369, implying that it can generate a 1.84 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 0.62HorizonTargetOdds Up 0.62 
90.25%90 days
 0.62 
9.70%
Based on a normal probability distribution, the odds of Immunocellular Therapeutics to move above the current price in 90 days from now is about 9.7 (This Immunocellular Therapeutics probability density function shows the probability of Immunocellular OTC Stock to fall within a particular range of prices over 90 days) .

Immunocellular Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Immunocellular Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immunocellular Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunocellular Therapeutics' value.
InstituionSecurity TypeTotal SharesValue
Captrust Financial AdvisorsCommon Shares3.00.0
Captrust Financial AdvisorsCommon Shares25.00.0
Citadel Advisors LlcWarrants14.1 K1000
View Immunocellular Therapeutics Diagnostics

Immunocellular Therapeutics Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Immunocellular Therapeutics market risk premium is the additional return an investor will receive from holding Immunocellular Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Immunocellular Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Immunocellular Therapeutics' alpha and beta are two of the key measurements used to evaluate Immunocellular Therapeutics' performance over the market, the standard measures of volatility play an important role as well.

Immunocellular Stock Against Markets

Picking the right benchmark for Immunocellular Therapeutics otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Immunocellular Therapeutics otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Immunocellular Therapeutics is critical whether you are bullish or bearish towards Immunocellular Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immunocellular Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Efficient Frontier Now

   

Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
All  Next Launch Module

Immunocellular Therapeutics Corporate Directors

Immunocellular Therapeutics corporate directors refer to members of an Immunocellular Therapeutics board of directors. The board of directors generally takes responsibility for the Immunocellular Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Immunocellular Therapeutics' board members must vote for the resolution. The Immunocellular Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Gregg Lapointe - Independent DirectorProfile
Rahul Singhvi - Lead Independent DirectorProfile
Mark Schlossberg - Independent DirectorProfile
Anthony Lapointe - Independent DirectorProfile
Please see Risk vs Return Analysis. Note that the Immunocellular Therapeutics information on this page should be used as a complementary analysis to other Immunocellular Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Immunocellular OTC Stock analysis

When running Immunocellular Therapeutics price analysis, check to measure Immunocellular Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocellular Therapeutics is operating at the current time. Most of Immunocellular Therapeutics' value examination focuses on studying past and present price action to predict the probability of Immunocellular Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunocellular Therapeutics' price. Additionally, you may evaluate how the addition of Immunocellular Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
The market value of Immunocellular Therapeutics is measured differently than its book value, which is the value of Immunocellular that is recorded on the company's balance sheet. Investors also form their own opinion of Immunocellular Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Immunocellular Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunocellular Therapeutics' market value can be influenced by many factors that don't directly affect Immunocellular Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunocellular Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunocellular Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunocellular Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.